FDA Approves Juvmo, a Once-Daily Pill for Parkinson’s Born of Decades-Long D1 Receptor Research

The United States Food and Drug Administration has approved a new Parkinson’s disease medication that traces its origins to more than four decades of basic pharmacology research at the University of Virginia. The drug, tavapadon, will be marketed under the brand name Juvmo by the pharmaceutical company AbbVie and is expected to become available to patients in October. Its approval marks the culmination of a scientific journey that began in the early 1980s, when a young researcher at UVA noticed something that the entire field of dopamine pharmacology had overlooked, and it represents one of the most consequential translations of academic neuroscience into clinical medicine in recent memory.

Juvmo belongs to a class of compounds known as D1 dopamine receptor agonists, and its path to approval was pioneered by Richard B. Mailman, PhD, Professor of Pharmacology and Neuroscience at the University of Virginia School of Medicine. A vital companion contribution came from Xuemei Huang, MD, PhD, chair of the Department of Neurology at UVA Health, who is also Mailman’s wife. Huang designed and led the first successful clinical trial with a drug of this class, demonstrating that D1 agonists could be administered safely in human patients. Together, the husband-and-wife team carried an idea from a laboratory observation to a licensed therapy, a trajectory that very few academic discoveries ever complete.

To understand why Juvmo matters, it helps to understand how Parkinson’s disease works and why existing treatments fall short. More than 11 million people worldwide live with the condition, one of the fastest-growing age-related neurological disorders. Parkinson’s is driven by the gradual death of nerve cells that make and use dopamine, a chemical messenger essential for smooth, coordinated movement. As those cells die, patients develop tremor, stiffness, slowness, and difficulty moving. The disease raises the risk of falls and often brings fatigue, insomnia, memory loss, and impaired concentration. Despite decades of intensive research, no therapy has been found that stops the underlying degeneration; all current treatment manages symptoms.

The gold standard of symptomatic treatment has been levodopa, a precursor of dopamine that has served patients for nearly 60 years. Levodopa is effective, but it has a fundamental biological weakness: it requires some of the very nerve cells that are dying in Parkinson’s disease to be converted into dopamine and to exert its effect. As Mailman explained, this means the drug becomes harder to use and less effective as the disease progresses. In practical terms, patients need multiple doses per day, and the intervals between doses grow increasingly frequent over time. Roughly 70 percent of patients taking levodopa need their dose increased within the first year of treatment, a pattern that reflects the progressive loss of the cellular machinery the drug depends on.

Mailman’s decisive insight came in 1984. At the time, every dopamine agonist in development or clinical use targeted a specific subset of dopamine receptors called the D2-like family. His experiments suggested that the other major receptor family, the D1-like receptors, was actually responsible for most of levodopa’s beneficial effects. He further suspected that selectively targeting D1-like receptors would avoid many of the side effects that plagued the approved dopamine-agonist drugs of the era. That hypothesis, radical for its time, became the intellectual foundation on which tavapadon was eventually built. Rather than replacing dopamine wholesale, a D1 agonist could selectively switch on one specific signaling pathway in the brain, providing relief from motor symptoms while potentially sparing patients the complications of broader receptor activation.

Turning that insight into a medicine proved to be an odyssey. Mailman spent years approaching pharmaceutical companies, large and small, to convince them of the promise of D1-directed therapy, often against an industry-wide conviction that the Parkinson’s market was too small to justify the investment. A key turning point came when he found a receptive audience at Pfizer in a team led by David L. Gray, PhD, who was persuaded by the strength of Mailman’s data. That collaboration ultimately produced tavapadon, a molecule engineered by chemists to retain the therapeutic mechanism Mailman had identified while improving its pharmaceutical properties. Earlier D1 agonists could only be injected; the new compound could be formulated as a pill taken just once per day, a dramatic practical advance for patients managing a chronic, progressive disease.

Huang’s contribution addressed the clinical obstacle that had derailed previous attempts to exploit D1 receptors. She joined the research team in the late 1990s and designed a clinical study showing that D1 agonists could be administered in a way that avoided the blood pressure problems that had plagued earlier efforts. Her work established that the class could be given safely to patients, opening the door to the large-scale trials that followed. Her position as a neurologist and department chair also meant the basic pharmacology was continuously tested against the realities of patient care, a feedback loop that shaped how the drug was evaluated and, ultimately, how it will be used.

The clinical trial results that supported approval are striking. Among participants receiving Juvmo, 93 percent had not increased their dose of levodopa after 85 weeks of treatment, and 94 percent of patients with early Parkinson’s had not needed to start levodopa at all. For a disease in which the standard therapy typically demands escalation within months, those numbers suggest that Juvmo may meaningfully change the treatment trajectory. Because the D1 receptors that the drug targets do not themselves degenerate in Parkinson’s disease, the therapeutic mechanism remains intact even as the disease advances, unlike levodopa, which loses its substrate. Juvmo can be combined with levodopa, but it may also serve as an important new option for patients whose symptoms cannot be optimally controlled with existing regimens.

Huang emphasized that the drug’s target opens possibilities well beyond current approved use. Because the receptor Juvmo acts on does not degenerate in Parkinson’s, she said, the hope is that it will smooth out current treatment problems and allow symptomatic relief to continue for much longer periods. Her own research, she noted, suggests there may even be hope that the drug could help patients in very late stages of the disease, for whom no effective therapy currently exists, and the availability of Juvmo now makes it possible to test those ideas directly. Mailman and Huang continue to investigate other potential applications for tavapadon and other D1 drugs beyond the scope the FDA has approved so far, meaning the story of this receptor family is likely not finished.

For Mailman, the approval carries both professional and deeply personal weight. He recalled the frustration of believing there had been a breakthrough for Parkinson’s patients while struggling to get others to share that vision, and he paid tribute to Professor Steven Wyrick, a key early collaborator who was diagnosed with Parkinson’s disease but never lived to try a drug in which he believed. It would have made the long journey worthwhile, Mailman said, if this helps begin a new era of Parkinson’s treatment. The work also exemplifies the mission of UVA’s new Paul and Diane Manning Institute of Biotechnology, which aims to translate cutting-edge academic science into new drugs and treatments more quickly, benefiting patients across Virginia and far beyond. Few stories illustrate that translational ideal better than a hypothesis scribbled down in 1984, nurtured through decades of skepticism by two scientists married to both the idea and each other, finally arriving as a once-daily pill in the hands of patients.

Subject of Research: FDA approval of the D1 dopamine receptor agonist tavapadon (Juvmo) for Parkinson's disease, developed from decades of University of Virginia pharmacology research

Article Title: Decades of work by husband-and-wife team yields new Parkinson's drug

Article References: Decades of work by husband-and-wife team yields new Parkinson's drug. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Parkinson's disease, tavapadon, Juvmo, D1 dopamine receptor agonist, levodopa, FDA approval, University of Virginia, Richard B. Mailman, Xuemei Huang, dopamine pharmacology, clinical trials, neurology